Coxiella burnetii PI-LPS Specific Neutra™ Antibody Products

Are you grappling with challenges in detecting low-abundance antigens or achieving reliable neutralization in Coxiella burnetii studies? Creative Biolabs' C. burnetii PI-LPS specific Neutra™ antibody products leverage advanced hybridoma screening and epitope-specific engineering to deliver high-affinity antibodies, enabling accurate pathogen detection, mechanistic studies, and accelerated therapeutic discovery.

Introduction to C. burnetii PI-LPS

Coxiella burnetii Phase I lipopolysaccharide (PI-LPS) is a hallmark virulence factor expressed by the pathogen's virulent Phase I variants. This glycolipid is integral to bacterial persistence in host cells, immune evasion, and zoonotic transmission. Unlike Phase II LPS, PI-LPS retains a full-length O-antigen polysaccharide chain, which directly correlates with enhanced resistance to host defenses and the ability to establish chronic infections.

• Structural Complexity and Immunogenicity

The PI-LPS structure comprises lipid A, a core oligosaccharide, and an extended O-polysaccharide chain composed of repeating virenose and dihydrohydroxystreptose units. This O-antigen's unique glycosylation pattern is pivotal for masking bacterial surface proteins, thereby limiting antibody recognition. Cryo-EM studies reveal that the dense O-antigen layer sterically hinders phagolysosomal fusion, enabling C. burnetii survival in macrophages. The structural integrity of PI-LPS is critical for host cell adhesion, invasion, and intracellular replication.

Fig.1 Structure of PI-LPS.¹

• Host-Pathogen Interactions and Signaling Pathways

PI-LPS activates Toll-like receptor 4 (TLR4)-mediated pro-inflammatory signaling in host cells, triggering NF-κB and MAPK pathways. Paradoxically, prolonged exposure to PI-LPS downregulates MHC-II expression and impairs antigen presentation, facilitating immune evasion. This dual role underscores its significance in both acute Q fever and chronic complications like endocarditis.

• Associated Diseases

C. burnetii is the causative agent of Q fever, a zoonosis characterized by flu-like symptoms, pneumonia, and hepatitis. Chronic Q fever, often linked to PI-LPS-expressing strains, can result in life-threatening endocarditis or vascular infections. Rapid detection and neutralization of PI-LPS are vital for managing outbreaks and preventing progression to severe disease.

Applications of Anti-C. burnetii PI-LPS Neutralizing Antibodies

• Rapid Diagnostic Development

Anti-PI-LPS antibodies enable point-of-care lateral flow assays for early Q fever detection in high-risk populations. Their specificity minimizes false positives in serological testing, crucial for differentiating acute and chronic infections.

• Vaccine Efficacy Evaluation

Quantify PI-LPS-specific IgM/IgG titers in vaccinated subjects to assess immune memory and durability. Antibodies are compatible with ELISA-based surrogate neutralization assays, streamlining vaccine candidate screening.

• Mechanistic Studies in Immune Evasion

Use neutralizing antibodies to dissect PI-LPS interactions with complement proteins or phagocytic receptors. Neutralization assays in macrophage models clarify how PI-LPS subverts lysosomal degradation pathways.

• Therapeutic Antibody Engineering

Our antibodies serve as templates for humanized monoclonal antibody (mAb) development. Preclinical studies demonstrate that engineered mAbs reduce bacterial load in persistent infection models, supporting their use in adjunctive therapies for chronic Q fever.

Our Anti-PI-LPS Antibodies

Creative Biolabs provides C. burnetii PI-LPS specific Neutra™ antibody products, which are engineered to overcome the challenges of Q fever research and drug development. With unmatched specificity and functional validation, these antibodies empower researchers to advance diagnostics, therapeutics, and mechanistic insights. Our PI-LPS-specific neutralizing antibodies are meticulously validated for epitope specificity, cross-reactivity, and functional efficacy. These antibodies target terminal O-antigen residues, disrupting bacterial adhesion and promoting opsonophagocytosis. Key features include:

- High Neutralization Potency: Antibodies block TLR4-mediated cytokine storms, mitigating inflammatory tissue damage.

- Diagnostic Precision: Detect PI-LPS in clinical samples with 99% specificity, distinguishing Phase I from Phase II strains.

- Therapeutic Potential: Antibody-mediated opsonization enhances bacterial clearance in preclinical models.

Contact us today to explore custom solutions for your project.

REFERENCE

1. Beare, Paul A., et al. "Genetic mechanisms of Coxiella burnetii lipopolysaccharide phase variation." PLoS Pathogens 14.3 (2018): e1006922. Distributed under Open Access license CC0 1.0, without modification. https://doi.org/10.1371/journal.ppat.1006922